Print Page     Close Window     
6-K
MESOBLAST LTD filed this Form 6-K on 08/31/2018
Entire Document
 

Slide 29

CY 2018 corporate milestones MSC-100-IV for Acute Graft versus Host Disease Successfully met Day 28 primary end point pediatric Phase 3 trial (Q1 CY18) Day 100 survival/safety data pediatric Phase 3 trial (Q2 CY18) Day 180 survival/safety data pediatric Phase 3 trial (Q3 CY18) Pre-BLA meeting (Q4 CY18) MPC-150-IM for Advanced and End-Stage Heart Failure Phase 2b trial full 12 month database lock in end-stage heart failure patients with LVADs (Q3 CY18) Phase 2b results presentation expected at major cardiovascular conference (Q4 CY18) Phase 3 trial in advanced heart failure enrollment completion (H2 CY18) MPC-06-ID for Chronic Low Back Pain Phase 3 trial completed enrollment (Q1 CY18) Completed non-dilutive transactions for commercialization of MSC-100-IV (remestemcel-L) Establish regional commercial partnerships Establish global commercial partnerships


Copyright © 2015 Mesoblast Inc.